Unrestrained poly-ADP-ribosylation provides insights into chromatin regulation and human disease.


Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
17 06 2021
Historique:
received: 04 08 2020
revised: 25 02 2021
accepted: 29 04 2021
pubmed: 22 5 2021
medline: 21 7 2021
entrez: 21 5 2021
Statut: ppublish

Résumé

ARH3/ADPRHL2 and PARG are the primary enzymes reversing ADP-ribosylation in vertebrates, yet their functions in vivo remain unclear. ARH3 is the only hydrolase able to remove serine-linked mono(ADP-ribose) (MAR) but is much less efficient than PARG against poly(ADP-ribose) (PAR) chains in vitro. Here, by using ARH3-deficient cells, we demonstrate that endogenous MARylation persists on chromatin throughout the cell cycle, including mitosis, and is surprisingly well tolerated. Conversely, persistent PARylation is highly toxic and has distinct physiological effects, in particular on active transcription histone marks such as H3K9ac and H3K27ac. Furthermore, we reveal a synthetic lethal interaction between ARH3 and PARG and identify loss of ARH3 as a mechanism of PARP inhibitor resistance, both of which can be exploited in cancer therapy. Finally, we extend our findings to neurodegeneration, suggesting that patients with inherited ARH3 deficiency suffer from stress-induced pathogenic increase in PARylation that can be mitigated by PARP inhibition.

Identifiants

pubmed: 34019811
pii: S1097-2765(21)00357-9
doi: 10.1016/j.molcel.2021.04.028
pmc: PMC8221567
mid: NIHMS1709114
pii:
doi:

Substances chimiques

Chromatin 0
Adenosine Diphosphate Ribose 20762-30-5
Poly Adenosine Diphosphate Ribose 26656-46-2
DNA 9007-49-2
Glycoside Hydrolases EC 3.2.1.-
ADPRS protein, human EC 3.2.1.143
poly ADP-ribose glycohydrolase EC 3.2.1.143

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2640-2655.e8

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R016836/1
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA047904
Pays : United States
Organisme : Wellcome Trust
ID : 203141/Z/16/Z
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R007195/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C35050/A22284
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 210634
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400653
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 210641/Z/18/Z
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : R01 CA207209
Pays : United States
Organisme : Wellcome Trust
ID : 101794
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Nat Commun. 2020 Jul 7;11(1):3391
pubmed: 32636369
PLoS Biol. 2018 Jul 3;16(7):e2005970
pubmed: 29969450
Mol Cell. 2017 Mar 2;65(5):932-940.e6
pubmed: 28190768
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
BMC Biotechnol. 2013 Nov 20;13:104
pubmed: 24256843
Cell Rep. 2018 Aug 28;24(9):2493-2505.e4
pubmed: 30157440
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Elife. 2018 Feb 26;7:
pubmed: 29480802
Nat Commun. 2012 Jun 06;3:878
pubmed: 22673905
Mol Cell. 2011 Jan 7;41(1):46-55
pubmed: 21211722
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Cell. 2020 Nov 12;183(4):1086-1102.e23
pubmed: 33186521
J Biol Chem. 1997 May 2;272(18):11895-901
pubmed: 9115250
Mol Cell Proteomics. 2019 May;18(5):1010-1026
pubmed: 30798302
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Sci Adv. 2019 Apr 10;5(4):eaav4340
pubmed: 30989114
Nat Commun. 2013;4:2164
pubmed: 23917065
Cell Rep. 2020 Sep 22;32(12):108176
pubmed: 32966781
Cell Chem Biol. 2018 Dec 20;25(12):1533-1546.e12
pubmed: 30472116
Nat Struct Mol Biol. 2020 Dec;27(12):1152-1164
pubmed: 33046907
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830864
J Cell Biol. 2006 Jan 30;172(3):363-72
pubmed: 16431929
Cancer Cell. 2019 Mar 18;35(3):519-533.e8
pubmed: 30889383
Nat Chem Biol. 2018 Sep;14(9):837-840
pubmed: 30013063
Nat Chem Biol. 2016 Dec;12(12):998-1000
pubmed: 27723750
Mol Cell. 2016 Feb 18;61(4):547-562
pubmed: 26895424
Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17699-704
pubmed: 15591342
Genome Biol. 2014;15(12):550
pubmed: 25516281
Trends Cancer. 2020 Mar;6(3):247-260
pubmed: 32101727
Genes Dev. 2020 Mar 1;34(5-6):360-394
pubmed: 32029455
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):82-6
pubmed: 14676324
Nature. 2020 Sep;585(7826):609-613
pubmed: 32939087
Nat Commun. 2019 Dec 11;10(1):5654
pubmed: 31827085
Science. 2009 Sep 4;325(5945):1240-3
pubmed: 19661379
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18475-80
pubmed: 20937877
DNA Repair (Amst). 2017 Apr;52:81-91
pubmed: 28254358
Cancers (Basel). 2020 Jan 11;12(1):
pubmed: 31940791
Cancer Res. 1999 Sep 1;59(17):4175-9
pubmed: 10485449
Science. 2011 Jun 17;332(6036):1443-6
pubmed: 21680843
J Virol. 2012 Aug;86(15):8259-68
pubmed: 22623791
Genes Dev. 2020 Mar 1;34(5-6):285-301
pubmed: 32029453
Methods Mol Biol. 2011;780:209-26
pubmed: 21870263
Mol Cell. 2018 Jul 19;71(2):319-331.e3
pubmed: 29983321
Nat Commun. 2017 Dec 12;8(1):2055
pubmed: 29234005
Genes Dev. 2020 Mar 1;34(5-6):254-262
pubmed: 32029457
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18964-9
pubmed: 24191052
EMBO J. 2013 May 2;32(9):1225-37
pubmed: 23481255
Nucleic Acids Res. 2017 Aug 21;45(14):8129-8141
pubmed: 28854736
Am J Hum Genet. 2018 Sep 6;103(3):431-439
pubmed: 30100084
Genes Dev. 2020 Mar 1;34(5-6):302-320
pubmed: 32029452
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Nat Commun. 2020 Feb 6;11(1):752
pubmed: 32029722
J Biol Chem. 2006 Jan 13;281(2):705-13
pubmed: 16278211
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Biol Chem. 1989 Aug 25;264(24):14382-5
pubmed: 2503517
Mol Cell Biol. 2015 Mar;35(5):856-65
pubmed: 25535335
Methods Mol Biol. 2017;1608:3-18
pubmed: 28695499
Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12
pubmed: 29894693
Nature. 2020 Mar;579(7800):598-602
pubmed: 32028527
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Biochemistry. 2017 Dec 5;56(48):6305-6316
pubmed: 29053245
Trends Genet. 2016 Jan;32(1):42-56
pubmed: 26704082
J Biol Chem. 1999 Jun 18;274(25):17860-8
pubmed: 10364231
Nat Commun. 2018 Aug 13;9(1):3233
pubmed: 30104678
Cell Chem Biol. 2018 Dec 20;25(12):1562-1570.e19
pubmed: 30318463
Elife. 2017 Jun 26;6:
pubmed: 28650317
ACS Chem Biol. 2013 Jul 19;8(7):1567-75
pubmed: 23631432
FEBS J. 2017 Sep;284(18):2932-2946
pubmed: 28383827
Nature. 2011 Sep 04;477(7366):616-20
pubmed: 21892188
Am J Hum Genet. 2018 Nov 1;103(5):817-825
pubmed: 30401461
Nucleic Acids Res. 2016 Feb 18;44(3):993-1006
pubmed: 26673700
Biochemistry. 1999 Mar 30;38(13):3948-53
pubmed: 10194306
Mol Cell. 2016 May 5;62(3):432-442
pubmed: 27067600
Cell Rep. 2018 Sep 25;24(13):3488-3502.e5
pubmed: 30257210
ACS Chem Biol. 2016 Nov 18;11(11):3179-3190
pubmed: 27689388
Genes Dev. 2017 Jan 15;31(2):101-126
pubmed: 28202539
Cancer Discov. 2020 Nov;10(11):1672-1689
pubmed: 32606138
J Biol Chem. 1993 Oct 25;268(30):22575-80
pubmed: 8226768

Auteurs

Evgeniia Prokhorova (E)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Thomas Agnew (T)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Anne R Wondisford (AR)

Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.

Michael Tellier (M)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Nicole Kaminski (N)

Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.

Danique Beijer (D)

Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.

James Holder (J)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Josephine Groslambert (J)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Marcin J Suskiewicz (MJ)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Kang Zhu (K)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Julia M Reber (JM)

Molecular Toxicology Group, Department of Biology, University of Konstanz, 78457 Konstanz, Germany.

Sarah C Krassnig (SC)

Molecular Toxicology Group, Department of Biology, University of Konstanz, 78457 Konstanz, Germany.

Luca Palazzo (L)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Shona Murphy (S)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Michael L Nielsen (ML)

Proteomics Program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark.

Aswin Mangerich (A)

Molecular Toxicology Group, Department of Biology, University of Konstanz, 78457 Konstanz, Germany.

Dragana Ahel (D)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Jonathan Baets (J)

Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; Laboratory of Neuromuscular Pathology, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Neuromuscular Reference Centre, Department of Neurology, Antwerp University Hospital, Antwerp, Belgium.

Roderick J O'Sullivan (RJ)

Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.

Ivan Ahel (I)

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK. Electronic address: ivan.ahel@path.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH